Abstract
Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.
| Original language | English |
|---|---|
| Pages (from-to) | 646-650 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 111 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 12 2014 |
Fingerprint
Keywords
- macrophages
- microenvironment
- sarcoma
- trabectedin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. / D'Incalci, M.; Badri, N.; Galmarini, C. M.; Allavena, P.
In: British Journal of Cancer, Vol. 111, No. 4, 12.08.2014, p. 646-650.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
AU - D'Incalci, M.
AU - Badri, N.
AU - Galmarini, C. M.
AU - Allavena, P.
PY - 2014/8/12
Y1 - 2014/8/12
N2 - Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.
AB - Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.
KW - macrophages
KW - microenvironment
KW - sarcoma
KW - trabectedin
UR - http://www.scopus.com/inward/record.url?scp=84906092874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906092874&partnerID=8YFLogxK
U2 - 10.1038/bjc.2014.149
DO - 10.1038/bjc.2014.149
M3 - Article
C2 - 24755886
AN - SCOPUS:84906092874
VL - 111
SP - 646
EP - 650
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 4
ER -